Selected article for: "abstract covid and acute respiratory distress syndrome"
Author: Chouw, Angliana; Milanda, Tiana; Sartika, Cynthia Retna; Kirana, Marsya Nilam; Halim, Danny; Faried, Ahmad
Title: Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19
  • Cord-id: vikn737v
  • Document date: 2021_3_10
    • ID: vikn737v
    Snippet: ABSTRACT: The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness,
    Document: ABSTRACT: The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19. LAY SUMMARY: The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.

    Search related documents:
    Co phrase search for related documents
    • activate immune cell and adaptive immunity: 1, 2
    • activation receptor and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
    • activation receptor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation receptor and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activation receptor and long term evaluation: 1
    • activation receptor and lung dysfunction: 1
    • activation receptor and lymph node: 1
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and administration route dose: 1
    • acute ards respiratory distress syndrome and lung dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and lung microenvironment: 1, 2, 3
    • acute ards respiratory distress syndrome and lymph node: 1, 2
    • acute ards respiratory distress syndrome and macrophage inflammatory protein: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome lead and lung dysfunction: 1
    • acute sars cov respiratory syndrome coronavirus and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and administration route: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and administration route dose: 1
    • acute sars cov respiratory syndrome coronavirus and long term evaluation: 1, 2, 3